Cellestia Biotech raises CHF 8 million from private investors and PPF Group (January 26).
[ Link to Press Release ]
Cellestia Biotech appointed Dr. Maximilien Murone as Chief Operating Officer.
Cellestia’s pipeline is supported by more than 15 years of research in the field of oncology and cancer stem cells biology conducted under the supervision of Prof. Freddy Radtke.
Cellestia Biotech AG was founded in 2014 as a spin-off from Ecole Polytechnique Fédérale de Lausanne, EPFL and is managed by a high-calibre team of academic and industry professionals.
Cellestia is actively engaged in the development of first-in-class mechanisms-based targeted therapeutics to address unmet medical needs, with an emphasis on oncology and immunological disorders.
Our anti-cancer CB-103 is a novel, first-in-class, oral pan-NOTCH inhibitor for treatment of NOTCH dependent leukemia, lymphoma and solid tumors.
The company is managed by a senior management team with a proven track record in cancer biology discovery and research, and drug development, business development and regulatory affairs.
In addition, an experienced team of industry and academic (university hospitals) consultants supports Cellestia’s drug development programs.
Lead development compound CB-103 is a first-in-class, oral pan-NOTCH inhibitor; it has been selected as Development Candidate to initiate preclinical development as targeted oncology therapy. To allow a personalized medicine approach, development of CB-103 will be complemented with a companion diagnostic to allow selection of the appropriate patients with NOTCH dependent disease.
Oral Pan-NOTCH inhibitor
It can be cell from breast, lung, blood, or any other tissue of the body that can become cancerous
In a lifetime, humans are exposed to DNA damage causing agents known as carcinogens
As a result of carcinogens exposure and DNA damage, certain cells acquire elevated level of Notch proteins and/or mutations in Notch proteins
The activation of Notch receptors results in Notch intracellular domain translocation into the nucleus, and activation of oncogenic programs
Once the Notch pathway is on, oncogenic programs transform healthy cells into cancerous cells
By directly targetting Notch in the nucleus, CB-103 is shutting down oncogenic programs
As a result of the treatment, Notch driven cancerous cells are eliminated
5NOTCH INTRACELLULAR DOMAIN
Step 5 - Conductive glass
Cellestia Biotech AG is in a unique position to capitalize on several factors to establish itself as a successful drug development company. An established track record of its founders and strategic advisors in cancer drug development and world-renowned expertise in Notch signaling provides depth to its expertise.
Cellestia’s ability to exploit Notch transcriptional activation complex modulation (both inhibitors and activators programs) provides a key competitive advantage over its competitors.
Financing for the initial research period has been secured in seed funding in May 2014 from private investors and, later from the Swiss Innovation Promotion Agency KTI/CTI. In addition, Cellestia Biotech AG is enjoying unique support by EPFL, in terms of the use of laboratories and support and the Technology Park Basel, where the Development Office is based.
To find out more about investment opportunities with Cellestia Biotech AG, contact us: [email protected]
Technology Park Basel
Innovation Park EPFL